TECH
Overvalued by 25.1% based on the discounted cash flow analysis.
Market cap | $7.59 Billion |
---|---|
Enterprise Value | $7.91 Billion |
Dividend Yield | $0.32 (0.661157024793389%) |
Earnings per Share | $1.07 |
Beta | 1.46 |
Outstanding Shares | 157,372,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 57.85 |
---|---|
PEG | -107.21 |
Price to Sales | 7.12 |
Price to Book Ratio | 4.15 |
Enterprise Value to Revenue | 6.54 |
Enterprise Value to EBIT | 46 |
Enterprise Value to Net Income | 60 |
Total Debt to Enterprise | 0.06 |
Debt to Equity | 0.23 |
No data
No data
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , No...